Principal Financial Group Inc. Has $38.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)
Principal Financial Group Inc. decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 6.7% in the fourth quarter, according to the company in its most recent ...
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $40.29 Consensus Target Price from Brokerages
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have been given a consensus rating of “Buy” by the seven ...
Johns Hopkins Medicine16d
Esophageal Atresia
Esophageal atresia is a rare, congenital (present at birth) disorder of the digestive system in which the esophagus, the tube that normally carries food from the mouth to the stomach, does not connect ...
gut.bmj25d
Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis
Background The risk of developing advanced neoplasia (AN; colorectal cancer and/or high-grade dysplasia) in ulcerative colitis (UC) patients with a low-grade dysplasia (LGD) lesion is variable and ...
Medscape26d
Barrett's Esophagus: Can Biomarkers Predict Progression to Malignancy?
Similar to the adenoma-carcinoma sequence of colorectal carcinomas, esophageal adenocarcinoma develops through progression from BE to low- and high-grade dysplasia, then to adenocarcinoma with ...
ascopubs.org27d
Optical coherence tomography and elastography for the visualization of architecture and stiffness differences in gastric cancer and dysplasia.
Effect of adjuvant radiotherapy after endoscopic resection of early esophagus cancer to prevent new intraluminal mucosal recurrence. This is an ASCO Meeting Abstract from the 2025 ASCO ...